Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced non-squamous NSCLC and previous clinical benefit on treatment with single agent Nivolumab.
Status: Open to Accrual
- Condition: Non-squamous non-small cell lung cancer
- Drug: Nivolumab
- Drug: Docetaxel
- Phase: Phase 2, randomized
Funding for this study is provided by Bristol-Myers Squibb.
Project Manager: Donna Sullivan, firstname.lastname@example.org; (317) 634-5842, ext. 40.